



# Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis

Jae-Ho Cheong\*, Han-Kwang Yang, Hyunki Kim, Woo Ho Kim, Young-Woo Kim, Myeong-Cherl Kook, Young-Kyu Park, Hyung-Ho Kim, Hye Seung Lee, Kyung Hee Lee, Mi Jin Gu, Ha Yan Kim, Jinae Lee, Seung Ho Choi, Soonwon Hong, Jong Won Kim, Yoon Young Choi, Woo Jin Hyung, Eunji Jang, Hyeseon Kim, Yong-Min Huh, Sung Hoon Noh\*




**Figure 2: Clinical subsets of patients with resectable gastric cancer by prognostic (A) or predictive (B) single patient classifiers**

Patients are assigned to the different subgroups on the basis of expression of four classifier genes assessed with real-time RT-PCR.

Immune high (GZMB+, WARS+); low risk and no benefit  
 Stem-like high (SFRP4+); high risk  
 Epithelial-high (CDX1+); CTx-benefit  
 No benefit relationship with SFRP4??

# Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis

Jae-Ho Cheong\*, Han-Kwang Yang, Hyunki Kim, Woo Ho Kim, Young-Woo Kim, Myeong-Cherl Kook, Young-Kyu Park, Hyung-Ho Kim, Hye Seung Lee, Kyung Hee Lee, Mi Jin Gu, Ha Yan Kim, Jinae Lee, Seung Ho Choi, Soonwon Hong, Jong Won Kim, Yoon Young Choi, Woo Jin Hyung, Eunji Jang, Hyeseon Kim, Yong-Min Huh, Sung Hoon Noh\*



**Figure 3: Overall survival in the validation cohort by single patient classifiers**  
625 of the 629 tumour samples from patients in the CLASSIC trial are included in these analyses; four samples were excluded during the RNA quality control evaluation. (A) Overall survival by treatment (D2 gastrectomy plus adjuvant chemotherapy or D2 gastrectomy only). (B) Overall survival by prognostic single patient classifier groups. (C) Overall survival by predictive single patient classifier, chemotherapy-benefit group, and treatment received. (D) Overall survival by predictive single patient classifier, no-benefit group, and treatment received. HR=hazard ratio.